Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 600 results for women's health

  1. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  2. NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

    Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

  3. Vaccine uptake in the general population (NG218)

    This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.

  4. Women with moderate to severe fibroids set to be offered new one-a-day treatment following final draft guidance from NICE

    Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.

  5. Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)

    NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .

  6. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  7. NICE calls for further research into the treatment of chronic lipoedema

    NICE has today issued interventional procedures guidance on the use of liposuction for the treatment of chronic lipoedema.

  8. Liposuction for chronic lipoedema (IPG721)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

  9. Integrated health and social care for people experiencing homelessness (NG214)

    This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

  10. Fetal alcohol spectrum disorder (QS204)

    This quality standard covers assessing and diagnosing fetal alcohol spectrum disorder (FASD) in children and young people. It also covers support during pregnancy to prevent FASD. It describes high-quality care in priority areas for improvement.

  11. What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

    of particular interest: ethnicity children and young people pregnant women vaccination status people with comorbidities people who are...

  12. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

    Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.

  13. Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS

    The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access has been recommended for routine use in the NHS by NICE in final draft guidance published today (24 February).

  14. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

  15. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.